{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T21:57:51Z","timestamp":1783720671174,"version":"3.55.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","clinicalnutritionespen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition ESPEN"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.clnesp.2025.01.056","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T08:28:49Z","timestamp":1738225729000},"page":"564-572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Efficacy and safety of combination of semaglutide and basal insulin in patients with of type 2 diabetes mellitus: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"66","author":[{"given":"Binbin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6918-807X","authenticated-orcid":false,"given":"Lanqiu","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohua","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clnesp.2025.01.056_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1161521","article-title":"Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments","volume":"14","author":"Ruze","year":"2023","journal-title":"Front Endocrinol"},{"issue":"6","key":"10.1016\/j.clnesp.2025.01.056_bib2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2217\/fca-2018-0045","article-title":"Type-2 diabetes mellitus and cardiovascular disease","volume":"14","author":"Henning","year":"2018","journal-title":"Future Cardiol"},{"issue":"1","key":"10.1016\/j.clnesp.2025.01.056_bib3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s13577-023-01007-0","article-title":"Treatment of type 2 diabetes mellitus with stem cells and antidiabetic drugs: a dualistic and future-focused approach","volume":"37","author":"Arte","year":"2024","journal-title":"Hum Cell"},{"issue":"10278","key":"10.1016\/j.clnesp.2025.01.056_bib4","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clnesp.2025.01.056_bib5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12933-022-01516-6","article-title":"Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management","volume":"21","author":"Ma","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clnesp.2025.01.056_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105782","article-title":"Anti-diabetic drugs and weight loss in patients with type 2 diabetes","volume":"171","author":"Lazzaroni","year":"2021","journal-title":"Pharmacol Res"},{"issue":"Suppl 1","key":"10.1016\/j.clnesp.2025.01.056_bib7","first-page":"S90","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.clnesp.2025.01.056_bib8","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2213-8587(21)00113-3","article-title":"Treatment of type 2 diabetes: challenges, hopes, and anticipated successes","volume":"9","author":"Nauck","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clnesp.2025.01.056_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.645507","article-title":"Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide","volume":"12","author":"Gallwitz","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.clnesp.2025.01.056_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110605","article-title":"Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"198","author":"Li","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clnesp.2025.01.056_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.645617","article-title":"Efficacy of semaglutide in a subcutaneous and an oral formulation","volume":"12","author":"Meier","year":"2021","journal-title":"Front Endocrinol"},{"issue":"18","key":"10.1016\/j.clnesp.2025.01.056_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22189936","article-title":"Oral semaglutide, the first ingestible glucagon-like peptide-1 receptor agonist: could it Be a magic bullet for type 2 diabetes?","volume":"22","author":"Kim","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.clnesp.2025.01.056_bib13","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists","volume":"38","author":"Ard","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.clnesp.2025.01.056_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metabol"},{"issue":"10","key":"10.1016\/j.clnesp.2025.01.056_bib15","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.2337\/dc14-0876","article-title":"Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes","volume":"37","author":"Diamant","year":"2014","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.clnesp.2025.01.056_bib16","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s13300-021-01034-w","article-title":"Once-daily oral semaglutide versus injectable GLP-1 RAs in people with type 2 diabetes inadequately controlled on basal insulin: systematic review and network meta-analysis","volume":"12","author":"Chubb","year":"2021","journal-title":"Diabetes Therapy: Research, Treatment and Education of Diabetes and Related Disorders"},{"key":"10.1016\/j.clnesp.2025.01.056_bib17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13098-018-0327-4","article-title":"Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?","volume":"10","author":"Moreira","year":"2018","journal-title":"Diabetol Metab Syndrome"},{"issue":"7","key":"10.1016\/j.clnesp.2025.01.056_bib18","article-title":"Comparison of efficacy and safety of Semaglutide combined with glycine and basal mealtime insulin in the treatment of newly diagnosed type 2 diabetes mellitus","author":"Duan","year":"2023","journal-title":"China Sci Technol J Database"},{"issue":"8","key":"10.1016\/j.clnesp.2025.01.056_bib19","article-title":"Clinical efficacy and safety of Semaglutide combined with insulin in the treatment of type 2 diabetes mellitus","volume":"34","author":"Tang","year":"2023","journal-title":"Modern Diagnosis and Treatment"},{"issue":"7","key":"10.1016\/j.clnesp.2025.01.056_bib20","article-title":"Effect of intensive treatment of Semaglutide combined with insulin pump on endocrine metabolism of type 2 diabetic patients","author":"Zhao","year":"2023","journal-title":"China Sci Technol J Database"},{"issue":"23","key":"10.1016\/j.clnesp.2025.01.056_bib21","article-title":"Effects of semaglutide combined with intensive insulin pump therapy on endocrine metabolism in patients with type 2 diabetes mellitus","volume":"40","author":"Li","year":"2022","journal-title":"Chinese Health Care"},{"issue":"12","key":"10.1016\/j.clnesp.2025.01.056_bib22","article-title":"Effectiveness of insulin combined with semaglutide in the treatment of diabetes mellitus","volume":"26","author":"Zhang","year":"2023","journal-title":"Diabetes New World"},{"issue":"6","key":"10.1016\/j.clnesp.2025.01.056_bib23","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.clnesp.2025.01.056_bib24","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/dom.14765","article-title":"Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial","volume":"24","author":"Kellerer","year":"2022","journal-title":"Diabetes Obes Metabol"},{"issue":"8","key":"10.1016\/j.clnesp.2025.01.056_bib25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.JAA.0000669456.13763.bd","article-title":"Long-acting GLP-1 RAs: an overview of efficacy, safety, and their role in type 2 diabetes management","volume":"33","author":"Chun","year":"2020","journal-title":"JAAPA : Off J Am Acad Physician Assistants (JAAPA)"},{"issue":"4","key":"10.1016\/j.clnesp.2025.01.056_bib26","doi-asserted-by":"crossref","first-page":"626","DOI":"10.2174\/1871530320666200705211224","article-title":"Fixed-ratio combinations of basal insulin and GLP-1RA in the management of type 2 diabetes mellitus: highlights from the literature","volume":"21","author":"Lisco","year":"2021","journal-title":"Endocr, Metab Immune Disord: Drug Targets"},{"issue":"4\u20135","key":"10.1016\/j.clnesp.2025.01.056_bib27","first-page":"213","article-title":"IcoSema: unveiling the future of diabetes management from a clinical pharmacology perspective","volume":"35","author":"Seetharaman","year":"2024","journal-title":"J\u00a0Basic Clin Physiol Pharmacol"},{"issue":"12","key":"10.1016\/j.clnesp.2025.01.056_bib28","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/dc19-0898","article-title":"Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial","volume":"42","author":"Zinman","year":"2019","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.clnesp.2025.01.056_bib29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/dom.14863","article-title":"Semaglutide for the treatment of overweight and obesity: a review","volume":"25","author":"Bergmann","year":"2023","journal-title":"Diabetes Obes Metabol"},{"issue":"5","key":"10.1016\/j.clnesp.2025.01.056_bib30","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","article-title":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials","volume":"45","author":"Aroda","year":"2019","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.clnesp.2025.01.056_bib31","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.clnesp.2025.01.056_bib32","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.clnu.2024.12.004","article-title":"Beyond fat: does semaglutide affect lean mass?","volume":"44","author":"Jamialahmadi","year":"2024","journal-title":"Clin Nutr"},{"issue":"5","key":"10.1016\/j.clnesp.2025.01.056_bib33","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s11695-024-07175-8","article-title":"Glucagon-like peptide-1 receptor agonists in post-bariatric surgery patients: a systematic review and meta-analysis","volume":"34","author":"Dutta","year":"2024","journal-title":"Obes Surg"},{"issue":"5","key":"10.1016\/j.clnesp.2025.01.056_bib34","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/14656566.2024.2343092","article-title":"A\u00a0systematic review of the effect of semaglutide on lean mass: insights from clinical trials","volume":"25","author":"Bikou","year":"2024","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.clnesp.2025.01.056_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1240263","article-title":"Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study","volume":"14","author":"Volpe","year":"2023","journal-title":"Front Endocrinol"},{"issue":"6","key":"10.1016\/j.clnesp.2025.01.056_bib36","first-page":"1224","article-title":"[The GLP-1 analogue battle: effects of semaglutide 0,5 mg\/weekly versus liraglutide 3 mg\/daily on anthropometric parameters after 3 months in a real world-scenario]","volume":"41","author":"Pujol Calafat","year":"2024","journal-title":"Nutr Hosp"},{"issue":"2","key":"10.1016\/j.clnesp.2025.01.056_bib37","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/dom.14567","article-title":"Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes","volume":"24","author":"Schmidt","year":"2022","journal-title":"Diabetes Obes Metabol"},{"issue":"11","key":"10.1016\/j.clnesp.2025.01.056_bib38","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"Supplement_1","key":"10.1016\/j.clnesp.2025.01.056_bib39","article-title":"Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study","author":"Wilding","year":"2021","journal-title":"J\u00a0Endocrine Society"},{"key":"10.1016\/j.clnesp.2025.01.056_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156057","article-title":"The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation","volume":"161","author":"Stefanakis","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.clnesp.2025.01.056_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102624","article-title":"Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial","volume":"72","author":"Hansen","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.clnesp.2025.01.056_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1394506","article-title":"Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice","volume":"15","author":"Pantanetti","year":"2024","journal-title":"Front Endocrinol"},{"issue":"10","key":"10.1016\/j.clnesp.2025.01.056_bib43","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2337\/dci23-0100","article-title":"Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition?","volume":"47","author":"Locatelli","year":"2024","journal-title":"Diabetes Care"},{"issue":"9922","key":"10.1016\/j.clnesp.2025.01.056_bib44","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0140-6736(13)62219-9","article-title":"The many faces of diabetes: a disease with increasing heterogeneity","volume":"383","author":"Tuomi","year":"2014","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.clnesp.2025.01.056_bib45","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2337\/dc17-0291","article-title":"Mitigating cardiovascular risk in type 2 diabetes with antidiabetes drugs: a review of principal cardiovascular outcome results of EMPA-REG outcome, leader, and SUSTAIN-6 trials","volume":"40","author":"Kaul","year":"2017","journal-title":"Diabetes Care"},{"issue":"15","key":"10.1016\/j.clnesp.2025.01.056_bib46","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1042\/CS20171299","article-title":"Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review","volume":"132","author":"Boyle","year":"2018","journal-title":"Clin Sci (Lond)."},{"issue":"19","key":"10.1016\/j.clnesp.2025.01.056_bib47","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.clnesp.2025.01.056_bib48","first-page":"891","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"376","author":"Marso","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clnesp.2025.01.056_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.645566","article-title":"Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes: findings from SUSTAIN 6 and PIONEER 6","volume":"12","author":"Nauck","year":"2021","journal-title":"Front Endocrinol"},{"issue":"4","key":"10.1016\/j.clnesp.2025.01.056_bib50","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40256-021-00515-4","article-title":"Glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus and cardiovascular disease: the past, present, and future","volume":"22","author":"Ferrari","year":"2022","journal-title":"Am J Cardiovasc Drugs : drugs, devices, and other interventions"},{"issue":"2","key":"10.1016\/j.clnesp.2025.01.056_bib51","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clnesp.2025.01.056_bib52","article-title":"GLP-1 receptor agonists and cardiovascular disease in patients with type 2 diabetes","volume":"2018","author":"Del Olmo-Garcia","year":"2018","journal-title":"J\u00a0Diabetes Res"},{"issue":"5","key":"10.1016\/j.clnesp.2025.01.056_bib53","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2213-8587(20)30038-3","article-title":"Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials","volume":"8","author":"Ghosh-Swaby","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.clnesp.2025.01.056_bib54","first-page":"2396","article-title":"Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect","volume":"20","author":"Iorga","year":"2020","journal-title":"Exp Ther Med"},{"issue":"Suppl 1","key":"10.1016\/j.clnesp.2025.01.056_bib55","first-page":"S98","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"}],"container-title":["Clinical Nutrition ESPEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457725000579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457725000579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T17:12:34Z","timestamp":1741972354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405457725000579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":55,"alternative-id":["S2405457725000579"],"URL":"https:\/\/doi.org\/10.1016\/j.clnesp.2025.01.056","relation":{},"ISSN":["2405-4577"],"issn-type":[{"value":"2405-4577","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of combination of semaglutide and basal insulin in patients with of type 2 diabetes mellitus: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition ESPEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnesp.2025.01.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd on behalf of European Society for Clinical Nutrition and Metabolism.","name":"copyright","label":"Copyright"}]}}